Synendos Therapeutics

Curated by Signal

Developer of endocannabinoid modulators for the treatment of CNS disorders

Overview

Synendos Therapeutics is a developer of endocannabinoid modulators for the treatment of CNS disorders. It has developed pharmaceutical products to restore the natural function of the brain and treat neuropsychiatric disorders. The company is developing small molecules as selective endocannabinoid reuptake inhibitors that increase the levels of endogenous cannabinoids to treat CNS disorders caused by cannabinoid deficiency.

Key facts

Founded: 2018
Headquarters: Allschwil, Switzerland
Stage: Sign up to view
Industry: Health Technology

Business model

1 product or service: Sign up to view

Contact

Primary office: Sign up to view
Email: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Health Technology companies

Adira
Provider of an application to track the health of pregnant women
Health TechnologyZurich, Switzerland
DOMO Health
Cloud and AI-based data analysis tool for providers
Health TechnologyLausanne, Switzerland
Luciole Medical
Developer of brain oxygenation monitoring systems
Health TechnologyZurich, Switzerland

About Synendos Therapeutics

What does Synendos Therapeutics do?

Synendos Therapeutics is a developer of endocannabinoid modulators for the treatment of CNS disorders.

Where is Synendos Therapeutics headquartered?

Synendos Therapeutics is headquartered in Allschwil, Switzerland.

When was Synendos Therapeutics founded?

Synendos Therapeutics was founded in 2018.

Which sector is Synendos Therapeutics in?

Synendos Therapeutics operates in Health Technology.

Who are Synendos Therapeutics's competitors?

Companies similar to Synendos Therapeutics include Adira, DOMO Health, and Luciole Medical.